Novo Nordisk Insulin Products

Novo Nordisk Has Probably Declined Enough

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments. Click to read why NVO stock is a Buy.

The Wall Street Journal on MSN · 2d

Novo Nordisk Outlook Provides Some Welcome Relief

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing capacity constraints and fears over the U.S. demand outlook for Wegovy.

Business Insider · 1d

Novo Nordisk (0QIU) Gets a Buy from UBS

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of

The Motley Fool · 1d

Why Novo Nordisk Stock Is Soaring Today

Novo Nordisk reported $40.5 billion in sales for 2024, surpassing Wall Street’s expectations. Its success was driven by its two GLP-1 drugs, Ozempic and Wegovy. The company is in a race with rival drugmakers to deliver GLP-1s in pill form.

WRAL · 1d

Novo Nordisk Coverage

Business Insider · 2d

Novo Nordisk (NVO) Receives a Buy from TD Cowen

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report). The company’s

10d

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

KARE 1111d

Novo Norodisk caps insulin prices at $35 for Minnesotans

MINNESOTA, USA — If you or your loved one relies on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday. Attorney General Keith ...

Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEO

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

NVO INVESTOR DEADLINE: Novo Nordisk Investors are Alerted to Contact BFA Law before the Imminent March 25 Class Action Deadline

New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

4NVO : Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...

Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

1don MSN

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results